52 / 54
Summary of Adverse Events
Keynote-189
Pembro+CT
vs CT
N = 405
All cause
404 (99.8 vs 99%)
Grade 3-5
272 (67.2 vs 65%)
Led to
discontinuation of
any treatment
112 (27.7 vs 14.9%)
AEs special interest
grade 3-4
Rash
7 (1.7%)
Pneumonitis
11 (2.7%)
Colitis
3 (0.7%)
Hypothyroidism
2 (0.5%)
Adverse Event
KEYNOTE 024
Update 2019
Pembro
Chemo
Treatment related
76.6%
90%
Grade ≥ 3
31.2%
53.3%
Discontinuation
13.6%
10.7%
Grade 5
1.3%
2%
Immune related
(All cause)
33.8%
5.3%